Нарушение фосфорно-кальциевого обмена у больных III-IV стадией хронической болезни почек
Диссертация
У больных с метаболической остеопатией выявлена достоверная отрицательная корреляция между иПТГ и уровнем 25(OH)D в сыворотке крови (р=0,02) между иПТГ и показателями минеральной плотности кости (р<0,001). Прямых корреляций между концентрацией 25(OH)D и показателями минеральной плотности кости не обнаружено, свидетельствуя, что 25(OH)D влияет на минеральную плотность кости через ПТГ. Поскольку… Читать ещё >
Список литературы
- Айламазян Э.К., Зазерская И. Е., Асеев М. В., и др. Остеопороз: генетическая предрасположенность, современная диагностика, профилактика. // Методическое пособие. Изд. СПБГУ. — 2003. -С. 32.
- Барабанова Т.А., Пенчук Н. А. Миокард, паратиреоидный гормон и хроническая почечная недостаточность. // Нефрология. 1998. — № 2.- Том. 2. — С. 88−94.
- Древаль А.В., Марченкова Л. А., Мылов Н. М., и др. Сравнительная информативность денситометрии осевого и периферического скелета и рентгенографии в диагностике постменопаузального остеопороза. // Остеопороз и остеопатии. 1999. — № 1. — С. 25−28.
- Ванд ер А. Регуляция обмена кальция и фосфора. // Физиология почек (перевод с англ.). СПб: Издательство «Питер». — 2000. — С. 214−224.
- Волгина Г. В., Перепеченных Ю. В. Паратиреодный гормон универсальный уремический токсин. // Нефрология и диализ. 2000.- Том. 2. № 2, — С. 32−38.
- Волгина Г. В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина Д. // Нефрология и диализ. -2004. Том.-б. — № 2. — С. 116−126.
- Ермоленко В.М. Фосфорно-кальциевый обмен и почки. // Нефрология: Руководство для врачей. / Под ред. И. Е. Тареевой. М.: Медицина.- 2000. С. 62−75.
- Ермоленко В.М., Родионова С. С., Павлова Е. А., и др. Спектр и лечение ренальной остеодитрофии у больных на постоянномамбулаторном перитонеальном диализе. // Нефрология и диализ.- 2004. Том. — 6. — № 2. — С. 164−169.
- Наточин Ю.В. Механизмы мочеобразования. // Нефрология: Руководство для врачей. / Под ред. И. Е. Тареевой. М.: Медицина.- 2000. С. 24−48.
- Некачалов В.В. Патология костей и суставов. // Руководство. СПБ: Сотис. — 2000. — С. 288.
- Птак С.М. Денситометрия: интерпретация результатов исследования. Методические указания Международного общества клинической денситометрии. // Остеопороз и Остеопатии. 2004. — № 2. — С. 11−13.
- Родионова С.С., Морозов А. К. Возможности и ошибки неинвазивной количественной оценки массы костной ткани для диагностики остеопороза. // Остеопороз и Остеопатии. 2005. — № 1. — С. 41−45.
- Рожинская Л.Я. Вторичный гиперпаратирсоз и почечные остеопатии при хронической почечной недостаточности. // Нефрология и диализ. 2000.-Том. -2. — № 4. — С. 241−247.
- Розен В.Б. Основы эндокринологии. М.: Изд. МГУ. 1994. — С. 384.
- Рубин М.П., Чечурин Р. Е. Влияние исследования минеральной плотности кости (МПК) в стандартных локализациях и дополнительных измерений МПК на установление диагноза остеопороза. // Остеопороз и Остеопатии. 2005. — № 2. — С. 21−24.
- Сморщок В.Н., Кузнецов Н. С., Рожинская Л. Я., и др. Вторичный гиперпаратиреоз у больных с терминальной стадией хроническойпочечной недостаточности. // Проблемы эндокринологии. 2003.- Том. -49. № 2. — С. 31−37.
- Франке Ю., Рунге Г. Остеопороз (перевод с нем.). М.: Медицина.- 1995.-С. 304.
- Шотемор Ш. Ш., Третьяков А. Е., Кулаков Т. П. Рентгенодиагностика нефрогенной остеодистрофии. // Вестник рентгенологии. 1984. — № 3. -С. 5−13.
- Ahmed А.1.Н., Blake G.M., Rymer J.M., et al. Screening for osteopenia and osteoporosis: Do accepted normal ranges lead to overdiagnosis? // Osteoporos. Int. 1997. — Vol. 7. — P. 432−438.
- Almaden Y., Hernandez A., Torregrosa V., et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. // J. Am. Soc. Nephrol. 1998. — Vol. 9. — P. 1845−1852.
- Almaden Y., Canalejo A., Ballesteros E., et al. Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. // J. Am. Soc. Nephrol. 2000. -Vol. 11. — P. 1712−1718.
- Amann K., Ritz E., Wiest G., et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J. Am. Soc. Nephrol.- 1994.-Vol.4.-P. 1814−1819.
- Amiel C., Escoubet В., Silve C., et al. Hypo-hyperphosphataemia. In: The Oxford Textbook of Clinical Nephrology on CD-ROM. // Oxford University Press. 1997.
- Arnaud C.D. Hyperparathyroidism and renal failure. I I Kidney int. 1973.- Vol. 4. P. 89−95.
- Bai X., Miao D., Li J., et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. // Endocrinol.- 2004. Vol. 145. — P. 5269−5279.
- Baker L.R., Abrams L., Roc C.J., et al. l, 25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. // Kidney int.- 1989.-Vol. 35(2).-P. 661−9.
- BakrA.M. Bone mineral density and bone turnover markers in children with chronic renal failure. // Pediatr. Nephrol. 2004. — Vol. 19. — P.1390−93.
- Benet-Pages A., Orlik P., Strom Т., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. // Hum. Mol. Genet. 2005. — Vol. 14. — P. 385−390.
- Bianchi M.L., Colantonio G., Montesano A., et al. Bone mass status in different degrees of chronic renal failure. // Bone. 1992. — Vol. 13. — Issue 3. — P. 225−228.
- Bianchi M.L., Colantonio G., Campanini F., et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. // Nephrol. Dial. Transplant. 1994. — Vol. 9. — P. 1595−1599.
- Bischoff H.A., Borchers M., Gudat F., et al. In situ detection of 1,25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem 2001. — Vol. 33. — P. 19−24.
- Bonnic S.L. Bone densitometry in clinical practice €). II Humana Press Inc. -2004.-P. 411.
- Bouchard J., Ouimet D., Vallee M., et al. Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations. // Int. Urol. Nephrol. 2008. — Vol. 481. — P. 983−988.
- Bricker N.S. On the pathogenesis of the uremic state. An exposition of the «trade-off hypothesis». // N. Engl. J. Med. 1972. — Vol. 286. — P. 1093−1099.
- Bro S. Olgaard K. Effects of excess PTH on nonclassical target organs. // Am. J. Kidney Dis. 1997. — Vol. 30. — P. 608−620.
- Brown A.J., Dusso A., Slatopolsky E. Vitamin D. // Am. J. Physiol. 1999. -Vol. 277.-P. F157-F175.
- Brown A.J., Finch J. Takahashi F., et al. Calcemic activity ofl9-Nor-1,25(OH)(2)D (2) decreases with duration of treatment. // J. Am. Soc. Nephrol. 2000. — Vol. 11. — P. 2088−2094.
- Brown E.M. PTH secretion in vivo and in vitro. Regulation by calcium and other secretagogues. // Miner. Electrolyte Metab. 1982. — Vol. 8. — P. 130.
- Brown E.M., Hebert S.C. Calcium-receptor-regulated parathyroid and renal function. // Bone. 1997. — Vol. 20. — P. 303.
- Brown J.P., Josse R.G. Clinical guidelines for the diagnosis and management of osteoporosis in Canada. // CMAJ. 2002. — Vol. 167 (suppl 10).-P. S51-S34.
- Bushinsky D.A. Hydrogen Ions. // Renal Osteodystrophy. New York: Lippincott-Raven. 1998. — P. l03−27.
- Cannata-Andia J.B., Gomez A. Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. // Nephrol. Dial. Transplant. 2002. — Vol. 17. — P. 1875−1878.
- Carlos P. G, Maria I.B.S, Maria E.L.D, et al. Bone disease in patients with chronic kidney disease under conservative management. // San Paulo Med. J. 2005. — Vol. 123 (2). — P.83−87.
- Carlsberg C., Quack M., Herdick M., et al. Central role of VDR conformations for understanding selective actions of vitamin D (3) analogues. // Steroids. 2001. — Vol. 66. — P. 213−221.
- Carter J.L., O’Riordan S.E., Eaglestone G. L, et al. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. // Nephrol. Dial. Transplant. 2008. — Vol. 23.- P.3554−3565.
- Casez J.P., Lippuner K., Horber F.F. et al. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. // Nephrol. Dial. Transplant. 2002. -Vol.7.-P. 1318−1326.
- Chen S., Sims G.P., Chen X.X., et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human В cell differentiation. J. Immunol.- 2007. Vol. 179. — P. 1634−1647.
- Cheng I., Klingensmith M.E., Chattopadhyay N., et al. Identification and localization of the extracellular calcium-sensing receptor in human breast. // J. Clin. Endocrinol. Metab. 1998. — Vol. 83. — P.703.
- Chertow G.M., Burke S.K., Lazarus J.M., et al. Poly (alylamine hydrochloride) (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. // Am. J. Kidney Dis. 1997. — Vol 29. — P. 66−71.
- Chiu K.C., Chu A., Go V.L., et al. Hypovitaminosis D is associated with insulin resistance and (3 cell dysfunction. // Am. J. Clin. Nutr. 2004.- Vol 79. — P. 820−825.
- Clinical practice guidelines for nutrition in chronic renal failure. National Kidney Foundation/K/DOQI. // Am. J. Kidney Dis. 2000. — Vol. 35(suppl).- P. S1-S140.
- Coburn J. W, Maung H. M, Elangovan L., et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. // Am. J. Kidney Dis.- 2004. Vol 43. — P.877−890.
- Coen G., Mazzaferro S., Ballanti P., et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-scctional study. //Nephrol. Dial. Transplant. 1996. — Vol. 11. — P. 813−819.
- Coen G., Ballanti P., Bonucci E., et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. //Nephron. 2002. — Vol. 91. — P. 103−111.
- Conchol M., Cigolini M., Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney disfunction. // Nephrol. Dial. Transplant.- 2008. Vol. 23. — P. 269−274.
- Chonchol M., Locatelli F., Abboud H.E., et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HC1 in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 2009.- Vol. 53. P. 197−207.
- Coyne D., Acharya M., Qiu P., et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. // Am. J. Kidney Dis. 2006. — Vol 47. — Issue 2. — P. 263−276.
- Cozzolino M., Lu Y., Finch J. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. // Kidney int. 2001. — Vol. 60. — P. 2109−17.
- Cozzolino M., Lu Y., Sato Т., et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. // Am. J. Physiol. Renal Physiol. 2005. — Vol. 289. — P. F1096-F1102.
- Craver L., Marco M.P., Martinez I., et al. Mineral metabolism parameters throughout chronic kidney disease stages 1−5: achievement of K/DOQI target ranges. // Nephrol. Dial. Transplant. 2007. — Vol. 22. -P. 1171−1176.
- Cundy T.F., Humphreys S., Watkins P.J., et al. Hyperparthyroid bone disease in diabetic renal failure. // Diabetes Res. 1990. — Vol. 14. — P. 191−196.
- Cunningham J., Makin II. How important is vitamin D deficiency in uraemia? //Nephrol. Dial. Transplant. 1997. — Vol. 12. — P. 16−18.
- Davies M.R., Hruska K.A. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney int. 2001. — Vol. 60. — P. 472−479.
- Dawson-Huges В., Heaney R.P., Holick M.F., et al. Estimates of optimal vitamin D status. // Osteoporos. Int. 2005. — Vol. 16. — P. 713−16.
- Denda M., Finch J., Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. // Am. J. Kidney Dis. 1996. — Vol. 28. — P. 596−602.
- Dhingra R., Sullivan L., Fox C., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. // Arch. Intern. Med. 2007. — Vol. 167. — P. 879−885.
- Drueke T.B. Renal osteodystrophy: management of hyper-phosphataemia. // Nephrol. Dial. Transplant. 2000. — Vol. 15. — Suppl 5: — P. 32−34.
- Drueke Т., Salusky I. The spectrum of renal osteodystrophy. // Oxford University Press. 2001. — P. 69−126, 185−280.
- Drueke T.B. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start dalysis. //Nephrol. Dial. Transplant. 2002. — Vol. 17 (Suppl). — P. 20−22.
- Drueke Т., David M., Mariano R. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. // Nephrol. Dial. Transplant. 2007. — Vol. 22. — P. 1828−1839.
- Dusso A.S., Pavlopoulos Т., Naumovich L. p21(WAFl) and transforming growth factor-alpha mediate dietary phosphate regulation on parathyroid cell growth. // Kidney int. 2001. — Vol. 59. — P. 855−65.
- Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. // Am. J. Physiol. Renal Physiol. 2005. — Vol 289. — P. F8-F28.
- Dusso A.S., Sato Т., Arcidiacono M.V., et al. Pathogenic mechanisms for parathyroid hyperplasia. // Kidney int. 2006. — Vol. 102 (Suppl). — P. S8-S11.
- Eastwood J.B., Harris E., Stamp T.C., et al. Vitamin D deficiency in the osteomalacia of chronic renal failure. // Lancet. 1976. — Vol. 2. — P. 12 091 211.
- Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. // J. Bone Miner. Res. 2002. — Vol. 17. — P. 2094−2105.
- Elder G.J., Mackun K. 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. // J. Bone Miner. Res. 2006. — Vol. 21. — P. 1778−1784.
- Endo I., lnoue D., Mitsui Т., et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003. -Vol. 144.-P. 5138−5144.
- Ersoy F.F. Osteoporosis in the elderly with chronic kidney disease. // Int. Urol. Nephrol. 2007. — Vol. 39. — P. 321−331.
- Feldman D., Pike J.W., Glorieux F.H. Vitamin D. 2nd edition Elsevier Academic Press Chapter 11. 2005.
- Fine A., Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome, and therapy. // Kidney int. 2002. — Vol. 61. — P. 2210−2217.
- Foldes A.J., Arnon E., Popovtzer M.M. Reduced speed of sound in tibial bone of hemodialysed patients: association with serum PTH level. // Nephrol. Dial. Transplant. -1996. Vol. 11. — P. 1318−1321.
- Foley R. Phosphorus comes of age as a cardiovascular risk factor. // Arch. Intern. Med. 2007. — Vol 167. — P. 873−874.
- Forster I., Kohler K., Biber J., et al. Modulation of renal type Ha Na+/Pi cotransporter kinetics by the arginine modifier phenylglyoxal. // J. Membr. Biol. 2002. — Vol. 15. — P. 18 785−18 796.
- Fox C.S., Larson M.G., Keyes M.J., et al. Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: The Framingham Heart Study. // Kidney int. 2004. -Vol. 66.-P. 2017−2021.
- Frazao J.M., Elangovan L., Maung H.M., et al. Intennittent doxercalciferol (1 a-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism. // Am. J. Kidney Dis. 2000. Vol. — 36. — P 550−561.
- Fukuda N., Tanaka H., Tominaga Y., et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. // J. Clin. Invest.- 1993.-Vol. 92.-P. 1436−1443.
- Galuska В., Zouch M., Germain N., et al. Constitutional thinness: unusual human phenotype of low bone quality. // J. Clin. Endocrinol. Metab. 2008. -Vol. 93.-P. 110−117.
- Garland J.S., Holden R.M., Groome P.A., et al. Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease. // Am. J. Kidney Dis. 2008. — Vol 52. — № 5. — P. 849−858.
- Gekle M. Renal tubule albumin transport. // Ann. Rev. Physiol. 2005.- Vol. 67. P. 573−594.
- Ghazali A., Fardellone P., Pruna A., et al. Is low plasma 25-(OII) vitamin D a major risk factor for hypeparathyroidism and Looser’s zones independent of calcitriol? // Kidney int. 1999. — Vol 55. — P. 2169−2177.
- Gilbreath A., Goode J.L., Hossli S.M. Effects of elevated PTH levels // Nephrol. Dial. Transpl. 2000. -Vol. 29. — № 12. — P. 803−809.
- Gogusev J., Duchambon P., Ногу В., et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. // Kidney int. 1997. — Vol. 51. — P. 328−336.
- Gomez A.C., Naves-Diaz M.L., Fernandez-Martin J.L., et al. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. // Kidney int. 2003. — Vol.63. — Suppl. 85. — P. S44-S48.
- Gomes K.P., Barello Silva M.I., Lette Duarte M.E., et al. Bone disease in patients with chronic kidney disease under conservative management. // San Paolo Med. J. 2005. — Vol. 123. — P. 83−87.
- Gonzalez E., Martin K. Coordinate regulation of РТЫ / PTHrP receptors by PTH and calcitriol in UMR 106−01 osteoblast-like cells. // Kidney int. -1996. Vol. 50. — P. 63−70.
- Gonzalez E.A., Sachdeva A., Oliver D.A., et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. // Am. J. Nephrol. 2004. — Vol. 24. — P 503−510.
- Goodman W.G., Coburn J.W. The use of 1.25 dihydroxyvitamin D3 in early renal failure. //Ann. Rev. Med. 1992. — Vol.43. — P. 227−237.
- Goodman W.G., Ramirez J.A., Belin T.R. et al. Development of adynamic bone in patients with secondary hyperparathyroidism alter intermittent calcitriol therapy. // Kidney int. 1994. — Vol. 46 (4). — P. 11 601 166.
- Goodman W.G., Frazao J.M., Goodkin D.A., et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. // Kidney int. 2000. — Vol. 58. — P. 436−445.
- Goodman W.G. Recent developments in the management of secondary hyperparathyroidism. // Kidney int. 2001. — Vol. 59. — P. 1187−1201.
- Goodman W.G. Calcimimetic agents for the treatment of secondary hyperparathyroidism. // Semin. Nephrol. 2004. — Vol. 24. — P. 460−463.
- Grotz W.H., Mundinger F.A., Rasenack J., et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. // Nephrol. Dial. Transplant. 1995. — Vol. 10. — P. 2096−2100.
- Guerin A.P., London G.M., Marchais S.J., et al. Arterial stiffening and vascular calcifications in end-stage renal disease. // Nephrol. Dial. Transplant. 2000. — Vol. 15. — P. 1014−1021.
- Gupta V., Verma V., Gupta R.K., et al. The spectrum of renal osteodystrophy: A clinical, biochemical, radiological and histopathological study. // JK Science. 2004. — Vol. 6. — № 3b. — P. 138−143.
- Ilamdy N.A., Kanis J.A., Beneton M.N., et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. // Brit. Med. J. 1995. — Vol. 310. — P. 358−363.
- Hamdy N.A.T. The spectrum of bone disease. // Nephrol. Dial. Transplant. 1995. — Vol. 10. — P. 14−18.
- Healy K.D., Frahm M.A., DeLuca H.F. 1,25-Dihydroxyvitamin D3 up-regulates the renal vitamin D receptor through indirect gene activation and receptor stabilization. // Arch. Biochem. Biophys. 2005. — Vol. 433.- P. 466−473.
- Hercz G., Sherard D.J., Chan W., Pei Y. Aplastic osteodystrophy: follow-up after 5 years. // J. Am. Soc. Nephrol. -1994. Vol. 5. — P. 851 (abstract).
- Hernandez D., Concepcion M.T., Lorenzo V., et al. Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance dialysis. // Nephrol. Dial. Transplant. 1994. — Vol. 9. — P. 517−523.
- Hernando N., Foster I., Biber J., Murer H. Molecular characteristics of phosphate transporters and their regulation. // Exp. Nephrol. 2000. — Vol. 8. — P. 366−375.
- Ho L.T., Sprague S.M. Renal osteodystrophy in chronic renal failure. // Semin. Nephrol. -2002. Vol. 22. — P. 488−493.
- Holick M.F. Vitamin D: importance in prevention of cancers, type 1 diabetes, heart disease and osteoporosis. // Am. J. Clin. Nutr. 2004. -Vol. 79.-P. 362−371.
- Holick M.F. Vitamin D for health and in chronic kidney disease. // Semin. Dial. 2005. — Vol 18. — P. 266−275.
- Horl W.H. Renal osteodystrophy: Role of calcimimetics. // Am. J. Kidney Dis. 2003. — Vol. 47. — P. S104-S107.
- Hsu C.Y., Chertow G.M. Elevations of serum phosphorus and potassium in mild-to-moderate chronic renal insufficiency. // Nephrol. Dial. Transplant. 2002. — Vol. 17. — P. 1419−1425.
- Hutchinson A.J., Whitehouse R.W., Boulton H.F., et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end stage renal disease. // Kidney int. 1993. — Vol. 44 (5). — P. 1071−7.
- Hutchison A.J., Laville M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. //Nephrol. Dial. Transplant. 2008. — Vol. 24. — P. 1−8.
- Ishimura E., Nishizawa Y., Inaba M., et al. Serum levels of 1.25-dihydroxyvitamin D, 24, 25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. // Kidney int. 1999. — Vol. 55. — P. 1019−1027.
- Jin Tian, Youhua Liu, Laura A., et al. Potential role of active vitamin D in retarding the progression of chronic kidney disease. // Nephrol. Dial. Transplant. 2007. — Vol. 22 (2). — P. 321−328.
- Jindal K., Chan C.T., Deziel C., et al. Mineral Metabolism. // J. Am. Soc. Nephrol. 2006. — Vol. 17. — Suppl. 1. — P. 11−15.
- Kanis J.A., Hamdy N.A.T. Hypo-hypercalcaemia. In: The Oxford Textbook of Clinical Nephrology on CD-ROM. // Oxford University Press. 1997.
- Kanis J.A., Gluer C.C. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of scicntific advisors, international osteoporosis foundation. // Osteoporos. Int.-2000. Vol. 1. -P. 192−202.
- KDIGO Clinical Practice Guidelines for the Diagnosis. Evaluation. Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney int. 2009. — Vol. 76 (Suppl. 113). — P. S50-S99.
- Kestenbaum В., Sampson J.N., Rudser K.D., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. // J. Am. Soc. Nephrol. 2005. — Vol. 16. — P. 520−528.
- Ketteler M., Rix M., Fan S., et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. // Clin. J. Am. Soc. Nephrol. 2008. -Vol.3.-P. 1125−1130.
- Khan A.A., Hodsman A.B., Papaioannou A., et al. // Management of osteoporosis in men: an update and case example. 2007.
- Kifor O., Moore F.D., Wang P., et al. Reduced immunostaining for the1. Л I e 1extracellular Ca sensing receptor in primary and uremic secondary hyperparathyroidism. // J. Clin. Endocrinol. Metab. — 1996. — Vol. 81. — P. 1598−1606.
- Kong Y., Boyle W., Penninger J., et al. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol. Cell Biol. 1999. — Vol 77. — P. 188−193.
- Kovesdy C.P., Ahmadzadeh S., Anderson J.E., et al. Obesity is associated with secondary hyperparathyroidism in men with moderate andsevere chronic kidney disease. // Clin. J. Am. Soc. Nephrol. 2007. — Vol. 2: — P. 1024−1029.
- Kovesdy C.P., Ahmadzadeh S., Anderson J.E., et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. // Arch. Intern. Med. 2008. — Vol. 168 (4). — P. 397−403.
- Kramer H., Toto R., Peshok R., et al. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. // J. Am. Soc. Nephrol. 2005. — Vol. 16. — P. 507−513.
- Kumar R. Vitamin D and calcium transport. // Kidney int. 1991. -Vol. 40.-P. 1177.
- Kurz P., Monier-Fugere M.C., Bognar B. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. // Kidney int. -1994.-Vol. 46.-P. 855−861.
- Lancaster L.E. Systemic manifestations of renal failure. // ANNA. Core Curriculum for Nephrology Nursing. Third Edition. 1995. — P. 539.
- Larsson Т., Davis S.I., Garringer H.J., et al. Fibroblast growth factor 23 mutants causing familal tumoral calcinosis are differentially processed. // Endocrinol. 2005. — Vol 146. — P. 3883−3891.
- Li Y.C., Qiao G., Uskokovic M., et al. Vitamin D: a negative regulator of the renin-angiotensin system and blood pressure. // J. Steroid Biochem. Mol. Biol. 2004. — Vol. 89−90. — P. 387−392.
- Lindberg J.S., Мое S.M., Goodman W.G., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. // Kidney int. 2003. — Vol. 63. -248−254.
- Lips P. Vitamin D deficiency and secondary hyperparathyroidism ir^ the elderly: Consequences for bone loss and fractures and therapeutics implications. // Endocrinol. Rev. 2001. — Vol. 22. — P. 477−501.
- Liu S., Guo R., Simpson L., et al. Regulation of fibroblastic growtii-^ factor 23 expression not degradation by PHEX. // J. Biol. Chem. 2003.- Vol. 278. P. 37 419−37 426.
- Liu S. Fibroblast growth factor 23 is a counter regulatory phosphatur-x
- Liu S. Pathogenic role of Fgf23 in Hyp mice. // Am. J. Physio X Endocrinol. Metab. 2006. — Vol. 291. — P. E38-E49.
- Llach F., Bover J. Renal osteodystrophy. // The kidney. Ed. by В. Brenner. New York. 1996. — Vol. 2. — 5th ed. — Chap.51. — P. 2187−2274.
- Llach F., Keshav G., Goldblat M.V., et al. Suppression of parathyrc>5r,
- Llach F., Yudd M. The importance of hyperphosphatemia in Т-Д-* 0 severity of hyperparathyroidism and its treatment in patients with chror^ renal failure. // Nephrol. Dial. Transplant. 1998. — Vol. 13. — P. 57−61.
- Llach F., Fernandez E. Overview of renal bone disease: Causes treatment failure, clinical observation, the changing pattern of bone Issic^xtl sand future therapeutic approach. // Kidney int. 2003. — Vol. 64. — Supll. 87.- P. SI 13−119.
- Lobao R., Carvalho A.B., Cuppari L., et al. High prevalance of low bone mineral density in pre-dialysis chronic kidney disease patients: bone hystomorphometric analysis. // Clin. Nephrol. 2004. — Vol. 62. — № 6. — P. 432−439.
- London G.M., Marty C., Marchais S.J., et al. Arterial calcification and bone histomorphometry in end-stage renal disease. // J. Am. Soc. Nephrol. -2004.-Vol. 15.-P. 1943−1951.
- London G.M., Marchais S.J., Guerin A.P., et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. // J. Am. Soc. Nephrol. 2008. — Vol. 19. — P. 1827−1835.
- Lopez H.S., Galceran Т., Chan Y.L., et al. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. // J. Clin. Invest. 1986. — Vol. 78. — P. 1097−1102.
- Lopez L, Aguilera Т.Е., Mendoza F.J., et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. // J. Am. Soc. Nephrol. 2006. — Vol. 17: — P. 795−804.
- Lorenzo S.V., Torrcgrosa V. Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis) // Nefrologia. 2008.- Vol. 28. Suppl 3. — P. 67−78.
- Malluche H.H., Werner E., Ritz E. Intestinal calcium absorption and whole-body calcium retention incipient and advanced renal failure. // Miner. Electrolyte Metab. 1978. — Vol. 1. — P. 263−270.
- Malluche H.H., Mawad H. Management of hyperphosphataemia of chronic kidney disease: Lessons from the past and future directions. // Nephrol. Dial. Transplant. 2002. — Vol. 17. — P. 1170−1175.
- Manolagas S.C., Kousteni S., Jilka R.L. Sex steroids and bone. // Rec. Progr. Horm. Research. 2002. — Vol. 57(1). — P. 385−409.
- Martin К.J., Gonzalez E.A. Vitamin D analogues for the management of secondary hyperparathyroidism. // Am. J. Kidney. Dis. 2001. — Vol. 38.- P. S34-S40.
- Martin K.J., Gonzalez E.A. Metabolic bone disease in chronic kidney disease. // J. Am. Soc. Nephrol. 2007. — Vol. 18. — P. 875−885.
- Martinez I., Saracho R., Montenegro J., Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. // Am. J. Kidney Dis. 1997. — Vol. 29. — P. 496−502.
- Massry S.G., Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. // Semin. Nephrol. 1994. — Vol. 14. — P, 219−231.
- McKenna M.J., Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D.//Osteoporos. Int.-1998.- Vol. 8. P. S.3-S.6.
- Melamed M.L., Michos E.D., Post W., et al. 25-hydroxyvitamin D levels and the risk of mortality in the general population. // Arch. Intern. Med. 2008. — Vol. 168. — P. 1629−1637.
- Menon V., Greene Т., Pereira A., et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. // Am. J. Kidney Dis.- 2005. Vol. 46. — P. 455−463.
- Merke J., Lucas P.A., Szabo A., et al. 1,25-dihydroxyvitamin D3 receptors and end organ response in experimental aluminium intoxication. // Kidney int. 1987. — Vol. 32.- P. 204−211.
- Messa P., Mioni G., Maio GD., et al. Derangement of acid-base balance in uremia and under hemodialysis. // J. Nephrol. 2001. — Vol. 14. — Suppl 4. — P. S12−21.
- Mihai R., Famdon J.R. Parathyroid disease and calcium metabolism. // Brit. J. Anaesth. 2000. — Vol. 85 (I). — P. 29−43.
- Mittal S.K., Dash S.C., Tivvari S.C., et al. Bone histology in patients with nephrotic syndrome and normal renal function. // Kidney int. -1999. -Vol. 55.-P. 1912−1919.
- Mizobuchi M., Hatamura I., Ogata H., et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. // J. Am. Soc. Nephrol. 2004. — Vol. 15. — P. 2579−2587.
- Moallem E., Kilav R., Silver J., et al. RNA-protein binding and post transcriptional regulation of parathyroid gene expression by calcium and phosphate. // J. Bone Chem. 1998. — Vol. 9. — P. 5253−5259.
- Мое S.M., Cunningham J., Bommer J., et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HC1. // Nephrol. Dial. Transplant. 2005. — Vol. 20. — P. 2186−2193.
- Мое S., Drueke Т., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). // Kidney int. 2006. -Vol. 69.-P. 1945−1953.
- Moranne O., Froissart M., Rossert J., et al. Timing of onset of CKD-related metabolic complications. // J. Am. Soc. Nephrol. 2009. — Vol. 20. -P. 164−171.
- Morosetti M., Jankovic L., Palombo G., et al. High-dose calcitriol therapy and progression of cardiac vascular calcifications. // J. Nephrol. -2008.-Vol.21.-P. 603−608.
- Morrisey J., Slatopolsky E. Effect of aluminium on parathyroid hormone secretion. //Kidney int. -1996. Vol. 29. — P.41−44.
- Movilli E., Zani R., Carli O., et al. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study. // Nephron. 2001.- Vol. 87. P. 257−262.
- Muntner P., Jones T.M., Hyre A.D., et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin. // J. Am. Soc. Nephrol. 2009. — Vol. 4. — P. 186−194.
- Murer H., Lotscher M., Kaissing В., et al. Renal brush border membrane Na/Pi=cotransport: molecular aspects in PTH dependent and dietary regulation. // Kidney int. — 1996. — Vol. 49. — P. 1769−73.
- Murer H., Hernando N., Forster I., Biber J. Molecular aspects in regulation renal phosphate reabsorbtion: the type Ha sodium/inorganic phosphate co-transporter as the key player. // Curr. Opin. Nephrol. Hypertens. 2001. — Vol. 10. — P. 555−561.
- National Kidney Foundation. K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. // Am. J. Kidney Dis. 2003. — Vol. 42. — Suppl 3. — P. Sl-201.
- Naveh-Many Т., Raue F., Grauer A., Silver J. Regulation of calcitonin gene expression by hypocalcemia^ hypercalcemia and vitamin D in the rat. //J. Bone Miner. Res. 1992. — Vol.7. — P.1233−1237.
- Naveh-Many Т., Rahamimov R., Livni N., Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. // J. Clin. Invest. 1995. — Vol. 96. — P. 1786−1793.
- Negri A.L. Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD. // Nephrol. Dial. Transplant.- 2009. Vol. 24(2). — P. 341−344.
- Neves K.R., Graciolli F.G., dos Reis L.M., et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function and bone in rats with renal failure. // Kidney int. 2004. — Vol. 66. — P. 2237−2244.
- Nilsson P. Bone disease in renal failure. Clinical and histomorphometric studies. // Scand. J. Urol. Nephrol. 1984. — Vol. 84 (Suppl). — P. 1−68.
- Nordal K.P., Dahl E., Halse J., et al. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: Can it prevent hyperparathyroid bone disease? // Nephrol. Dial. Transplant. 1995. — Vol. 10. — P. 203−206.
- Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999. — Vol. 96. — P. 507−515.
- Obatake N. Ishimura E., Tsuchida Т., et al. Annual change in bone mineral density in predialysis patients with chronic renal failure: significance of a decrease in serum 1.25 dihydroxyvitamin D. // J. Bone Miner. Metab. 2007. — Vol. 25. — P. 74−79.
- Official Positions of the International Society for Clinical Densitometry. // (c)Copyright ISCD. Supersedes all prior «Official positions» publications. 2007.
- Ogata IT, Ritz E., Odoni G., et al. Beneficial effects of calcimimetics on progression on renal failure and cardiovascular risk factors. // J. Am. Soc. Nephrol. 2003. — Vol. 14. — P. 959−967.
- Olgaard K., Lewin E. Use (or misuse) of vitamin D treatment in CKD and dialysis patients. // Nephrol. Dial. Transplant. 2008. — Vol. 23(6). — P. 1786−1789.
- Ott S.M. Aluminium-related osteomalacia. // Int. J. Artif. Organs. 1983.-Vol. 6.-P. 173−175.
- Parfitt A.M. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. // Curr. Opin. Nephrol. Hypertens. -2003. Vol. 12. — P. 387−403.
- Pascal H., Marc F., Gerard M., Anne B. What serum calcium can tell us and what it can’t. // Nephrol. Dial. Transplant. 2006. — Vol. 21. — P. 29−32.
- Pei Y., Hercz G., Greenwood C., et al. Risk factors for renal osteodystrophy: a multivariant analysis. // J. Bone Miner. Res. 1995. -Vol. 10.-P. 149−156.
- Perwad F., Azam N., Zhang M.Y., et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. // Endocrinol. 2005. — Vol. 146. — P. 5358−5364.
- Phan O., Ivanovski O., Nguyen-Khoa Т., et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E deficient (apoE-/-) mice. // Circulation. 2005. — Vol. 112. — P. 2875−2882.
- Pogoda P., Priemel M., Rueger J.M., Amling M. Bone remodeling: new aspects of a key process that controls skeletal maintenance and repair // Osteoporos. Int. 2005. — Vol. 16. — Suppl. 2. — P. 18−24.
- Potts J.T. Diseases of the parathyroid gland and other hyper- and hypocalcemic diseases. // Harrison’s principles of internal medicine. New York: McGraw-Hill. 2002. — 15th ed. — P. 2205−2226.
- Przedlacki J., Manelius J., Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one year treatment with calcitriol started in the predialysis phase of chronic renal failure. // Nephron. 1995. — Vol. 69. — P. 433−437.
- Quarles L.D., Sherrard, D.J., Adler S., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end stage renal disease. // J. Am. Soc. Nephrol. 2003. — Vol. 14. — P. 575−583.
- Ramos A.M., Albalate M., Vazquez S., et al. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. // Kidney int. -2008. Vol. 74. — Suppl 111. — P. S88-S93.
- Ray J.M., Squires P.E., Curtis SB., et al. Expression of the calcium-sensing receptor on human antral gastrin cells in culture. // J. Clin. Invest. 1997.-Vol. 99.-P. 2328.
- Reichel H., Deibert В., Schmidt-Gayk H., Ritz E. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. // Nephrol. Dial. Transplant. 1991. — Vol. 6. — P. 162−169.
- Reichel H. Current treatment options in secondary renal hyperparathyroidism. //Nephrol. Dial. Transplant. 2006. — Vol. 21(1). — P. 23−28.
- Reiss E., Canterbury J.M., Kanter A: Circulating parathyroid hormone concentration in chronic renal insufficiency. // Arch. Intern. Med. 1969. -Vol. 124. — P. 417−422.
- Ritter C.S., Finch J.L., Slatopolsky E.A., Brown A. J. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. // Kidney int. 2001. — Vol. 60. — P. 1737−1744.
- Ritter C.S., Armbrecht H.J., Slatopolsky E., et al. 25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. // Kidney int. 2006. — Vol. 70. — P. 654−659.
- Ritz E., Stefanski A., Rambausek M. The role of the parathyroid glands in the uremic syndrome. // Am. J. Kidney Dis. 1995. — Vol. 26(5). -P. 808−813.
- Rix M., Andreassen H., Eskildsen P., et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. // Kidney int. 1999. — Vol. 56. — P. 1084−1093.
- Rix M., Eskildsen P., Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. //Nephrol. Dial.Transplant. 2004. — Vol. 19. — P. 870−876.
- Robert F.R. CKD Series: Disturbances of mineral metabolism in chronic kidney disease. // Hospit. Physician. 2003. — Vol. 5. — P. 23−31.
- Rodriguez M., Nemeth E., Martin D. The calcium-sensing rcceptor: a key factor in the pathogenesis of secondary hyperparathyroidism. // Am. J. Physiol. Renal Physiol. 2005. — Vol. 288: — P. F253-F264.
- Rodriguez M. Felsenfeld A.J. PTH, FGF-23 and early CKD. // Nephrol. Dial. Transplant. 2008. -Vol. 23 (11). — P. 3391−3393.
- Rostand S.G., Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney int. 1999. — Vol. 56. — P. 383−392.
- Russell J., Lettieri D., Sherwood L.M. Suppression by l, 25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. // Endocrinol. 1986. -Vol. 119.-P. 2864−2866.
- Russo D., Miranda I., Ruocco C., et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. // Kidney int. 2007. — Vol. 72. — P. 1255−1261.
- Schaefer K., Umlauf E., Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by admistering calcitriol at night. // Am. J. Kidney Dis. 1992. — Vol. 9. — P. 460−464.
- Schwarz S., Trivedi B.K., Kalantar-Zadeh K., et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. // Clin. J. Am. Soc. Nephrol. 2006. — Vol. 1. — P. 825−831.
- Scragg R., Sowers M., Bell C. Third National Health and Nutrition Examination Survey: serum 25-hydroxyvitamin D, diabetes, and ethnicity. // Diabet. Care. 2004. — Vol. 27. — P. 2813−2818.
- Segersten U., Correa P., Hewison M., et al. 25-Hydroxyvitamin D3−1 alpha-hydroxylase expression in normal and pathological parathyroid glands. //J. Clin. Endocrinol. Metab. 2002. — Vol. 87. — P. 2967−2972.
- Sekkarie M. The impact of over-the-counter vitamin D supplements on vitamin D and parathyroid hormone levels in chronic kidney disease. // Clin. Nephrol. 2006. — Vol. 65. — P. 91−96.
- Sherrard D.J., Herez G., Pei Y., et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. // Kidney int. 1993. — Vol. 43.- P. 436−442.
- Shimada Т., Mizutani S., Muto Т., et al. Cloning and characterization of FGF-23 as a causative factor of tumor-induced osteomalacia. // Proc. Natl. Acad. Sci. USA. 2001. — Vol. 98. — P. 6500−6505.
- Shimada Т., Kakitani M., Yamazaki Y., et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. // J. Clin. Invest. 2004. — Vol. 113. — P. 561−568.
- Shimada Т., Hasegawa H., Yamazak Y., et al. Vitamin D receptor-independent FGF-23 actions in regulating phosphate and vitamin D metabolism. // Am. J. Physiol. Renal Physiol. 2005. — Vol. 289. — P. F1088-F1095.
- Shin S.K., Kim D.H., Kim H.S., et al. Renal osteodystrophy in predialysis patients: ethnic difference? // Perit. Dial. Int. 1999. — Supll 2.- P. S402-S407.
- Shoben A.B., Rudser K.D.D., de Boer I.H., et al. Association of oral calcitriol with improved survival in nondialyzed CKD. // J. Am. Soc. Nephrol. 2008. — Vol. 19. — P. 1613−1619.
- Silver J., Russell J., Sherwood L.M. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. // Proc. Natl. Acad. Sci. USA. 1985. -Vol. 82.-P. 4270−4273.
- Silver J., Naweh-Many Т., Mayer H., et al. Regulation by vitamin D metabolites of parathyroid gene transcription in vivo in rat. // J. Clin. Invest.- 1986.-Vol. 78.-P. 1296−1301.
- Silver J., Yalcindag C., Sela-Brown A., et al. Regulation of parathyroid honnone gene by vitamin D, calcium and phosphate. // Kidney int. 1999.- Vol.56. Suppl. 73. — P. S2-S7.
- Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell- 1997.-Vol 89.-P. 309−19.
- Simpson R.U., Weishaar R.E. Involvement of 1,25-dihydroxyvitamin D3 in regulating myocardial calcium metabolism: physiological and pathological actions. Cell Calcium 1988. — Vol. 9. — P. 285−292.
- Sitara D., Razzaque M.S., St-Arnaud R., et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in FGF23-null animals. // Am. J. Pathol. 2006. — Vol. 169. — P. 2161−2170.
- Slatopolsky E. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism // Nephrol. Dial. Transplant. 1998. — Vol. 13. — Suppl. 3. — P. S3-S8.
- Slatopolsky E., Bricker N.S. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. // Kidney int. 1973. — Vol. 4. — P. 141−145.
- Slatopolsky E., Caglar S., Gradowska L., et al. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease usingproportional reduction" of dietary phosphorus intake. 11 Kidney int. 1972. -Vol. 2. — P. 147−151.
- Slatopolsky E., Caglar S., Pennell J.P., et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. // J. Clin. Invest. 1971. — Vol. 50. — P. 492−499.
- Slatopolsky E., Delmez J. A. Pathogenesis of secondary hyperparathyroidism. // Am. J. Kidney Dis. 1994. — Vol. 23. — P. 229−236.
- Slatopolsky E., Finch J., Denda M., et al. Phosphate restriction prevents parathyroid cell growth in uremic rats. High phosphate directly stimulates PTH secretion in vitro. // J. Clin. Invest. 1996. — Vol. 97. — P. 2534−2540.
- Slatopolsky E., Finch J., Ritter C., et al. A new analog of calcitriol, 19-nor-D2 supresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. // Am. J. Kidney Dis. 1995. — Vol. 26. — P. 852−860.
- Somjen D., Weisman Y., Kohen F., et al. 25-hydroxyvitamin D3−1 alpha- hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. // Circulation. 2005. — Vol. 111.-P. 1666−1671.
- Spasovski G.B., Bervoets A.R., Behets G.J.S., et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. // Nephrol. Dial. Transplant. 2003. — Vol. 18. — P. 1159−1166.
- Sprague S.M., Llach F., Amdahl M., et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. // Kidney int. 2003. — Vol. 63. — P. 1483−1490.
- Stavroulopoulos A., Poster C.J., Roe S.D., et al. Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. // Nephrology. 2008.- Vol. 13. P. 63−67.
- Steddon S.J., Schroeder N.J., Cunningham J. Vitamin D analogues: how do they differ and what is their clinical role? // Nephrol. Dial. Transplant. 2001. — Vol. 16. — P. 1965−1967.
- Tanaka Y., Deluca H.F. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus.//Arch. Biochem. Biophys. 1973.- Vol. 154. P. 566−574.
- Teng M., Wolf M., Amdahl M., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. // J. Am. Soc. Nephrol. -2005.-Vol. 16.-P. 1115−1125.
- Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., et al. Hypovitaminosis D in medical inpatients. //N. Engl. J. Med. 1998. — Vol. 338. — P. 777−783.
- Torres A., Lorenzo V., Hernandez D. et al. Bone diseases in predalysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. // Kidney int. 1995. — Vol. 47. — P. 1434−1442.
- Toussaint N.D., Lau K.K., Strauss B.J., et al. Association between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. // Nephrol. Dial. Transplant. 2008. — Vol. 23 (2). — P. 586−593.
- Tsukamoto Y., Moriya R., Nagaba Y., et al. Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. // Am. J. Kidney Dis. 1995. — Vol. 25 (6). — P. 879−886.
- Varenna M., Binelli L., Zucchi F., et al. Prevalence of osteoporosis by educational level in cohort of menopausal women. // Osteoporos. Int.- 1999.-Vol. 9.-P. 236−241.
- Voormolen N., Noordzij M., Grootendorst C., et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. // Nephrol. Dial. Transplant. 2007. — Vol. 22. — P. 2909−2916.
- Wada M., Nagano N., Furuya Y., et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. // Kidney int. 2000. — Vol. 57. — P. 50−58.
- Warming L., Hassager C., Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. // Osteoporos. Int. 2002. — Vol. 13. — P. 105−112.
- Weisinger J.R., Bellorin-Font E. Postmenopausal osteoporosis in the dialysis patient. // Curr. Opin. Nephrol. Hypertens. 2003. — Vol 12. — P. 381−386.
- Weisman Y., Eisenberg Z., Leib L., et al. Serum concentrations of 24,25- dihydroxyvitamin D in different degrees of chronic renal failure. // Brit. Med. J. 1980. — Vol. 281. — P. 712−713.
- Widmer В., Gerhardt R.E., Harrington J.T., et al. Serum electrolyte and acid base composition. The influence of graded degrees of chronic renal failure. // Arch. Intern. Med. 1979. — Vol. 139. — P. 1099−1102.
- Yamashita Т., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. //Biochem. Biophys. Res. Commun. 2000.- Vol. 277. P. 494−498.
- Yang S., Smith C., Prahl J.M., DeLuca H.F. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch. Biochem. Biophys.- 1993.-Vol. 303.-P. 98−106.
- Yu S., Bruce D., Froicu M., et al. Failure of T cell homing, reduced CD4/CD8 alpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor КО mice. Proc. Natl. Acad. Sci. USA. 2008. — Vol. 105(52). — P. 20 834−9.
- Yumita S., Suzuki M., Akiba Т., et al. Levels of serum l, 25(OH)2D in patients with pre-dialysis chronic renal failure. // Tohoku J. Exp. Med. 1996.-Vol. 180.-P. 45−56.
- Zitterman A., Schleithoff S.S., Tenderich G., et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? //J. Am. Coll. Cardiol. 2003. — Vol. 41. — P. 105−112.